Tests lemborexant for sleep problems in people with epilepsy
Tests whether lemborexant improves sleep in adults with epilepsy.
Plain-language title generated from the registry record
Registry title: Lemborexant Treatment of Insomnia Linked to Epilepsy
Key facts
- Where
- Winnipeg, CanadaSee the site
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with epilepsy linked to sleep, to see whether Lemborexant can improve their sleep.
- Age
- 18 years or older
- Sex
- Men and women can join.
- Disease stage
- Sleep-related focal epilepsy.
- Earlier treatment
- Antiseizure medication must not have been changed in the month before the study or during it.
Main reasons for not taking part
- Pregnant or breastfeeding women
- Liver problems (hepatic impairment)
- Breathing problems (compromised respiratory function)
- History of complex sleep-related behaviour
- Psychiatric disorders with abnormal thinking, depression or suicidal thoughts
Read by machine on 12 November 2026.
Where in Canada
- Health Sciences CentreWinnipeg, CanadaContact: Marcus Ng, MD, FRCPCTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University of Manitoba
- Trial code
- NCT06262594
- Record updated
- 13 February 2025
- Original description
The goal of this clinical trial is to assess whether Lemborexant can improve sleep in patients with epilepsy.Read full original descriptionShow less
Lemborexant Treatment of Insomnia Linked to Epilepsy
The goal of this clinical trial is to assess whether Lemborexant can improve sleep in patients with epilepsy.
Inclusion: Sleep-related focal epilepsy; Contraception.
Exclusion: Changes in antiseizure medication 1 month before study protocol or during study protocol; Concomitant medications per SUNRISE1; Individuals with hepatic impairment; Individuals with a history of complex sleep-related behaviour; Individuals with a history of dependence or tolerance - abuse, dependence, rebound insomnia; Individuals with psychiatric disorders with abnormal thinking and behavioural changes, depression, or suicidal ideation; Individuals with rare hereditary diseases of galactose intolerance such as galactosemia or glucose-galactose malabsorption; Female participants who are pregnant or breastfeeding; Individuals with compromised respiratory function; Individuals with a diagnosis of narcolepsy.